Take care with 4CE. Fundamentals may not be as sound as people assume based on latest announcement. Still plenty of upside, but the project hasn't de-risked enough to warrant a re-rate in my opinion.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%
TLS Telstra to boost phone plan prices despite inflation – and despite claiming they wouldn't 2 months ago
